Zhejiang Jiaoke: the amount of newly signed orders in the first quarter was 9.488 billion yuan, and the order stock was sufficient

IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

2025: New Approaches to Global Traffic Acquisition

From impulsive decision-making to systematic analysis, traffic acquisition in cross-border e-commerce, content creation, and global gaming is no longer just a numbers game—it has become a battle of precision and efficiency. As traditional traffic operation strategies lose effectiveness, companies expanding overseas face a key challenge: how to achieve the highest conversions with the lowest cost.

Global Expansion Battle: The International Advances of BYD, United Imaging, and Trip.com

For those new to the outbound business, the term "going global" might be somewhat misleading. "Going global? Is it just foreign trade? What exactly does it mean?" This article will move beyond vague discussions and delve deeper into the path Chinese enterprises take when expanding overseas.

China's First Modified New Drug of Docetaxel Successfully Went to the US

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?